AstraZeneca claims that an oral lipid-lowering drug can drop bad cholesterol by more than 50%.

Jin10 data reported on April 2, that AstraZeneca (AZN.O) presented clinical data on a new lipid-lowering drug under investigation at the American College of Cardiology Annual Scientific Session held in Chicago. The interim trial data shows that a PCSK9 (proprotein convertase subtilisin/kexin type 9) oral lipid-lowering drug being developed by the company can reduce "bad cholesterol" by nearly 51%. AstraZeneca stated that patients taking this oral lipid-lowering drug once daily in addition to standard statin therapy can lower their low-density lipoprotein (LDL) cholesterol levels by nearly 51% after 12 weeks. LDL, also known as "bad cholesterol," is a major driver of cardiovascular events such as heart attacks and strokes.